Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027960 (
mole
)
21,279
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
It has been suggested that dynamically regulated expression of the
JARID1B
protein is required for the continuous growth of tumors and at the same time downregulated in melanoma. The majority of the data on a role of
JARID1B
in maintaining tumor growth has come from in-vitro and xenografting experiments, with only one immunohistochemical study involving human tissues. We compared
JARID1B
expression levels in human melanomas and benign nevi and analyzed patterns of spatial distributions of positive cells among different skin layers of the lesions. The expression of
JARID1B
was evaluated by immunohistochemistry in formalin-fixed paraffin-embedded samples of 30
nevi
, 27 primary melanomas, four lymph node metastases, and one local recurrence of melanoma. Staining for
JARID1B
protein was stronger in melanomas compared with
nevi
. We also found a significant difference in the spatial distribution of positive cells in individual skin layers of
nevi
and melanomas. Staining of melanocytes located in granular and spinous layers of
nevi
was observed very rarely, whereas for melanomas, the mean percentage fractions of positive cells present in these layers exceeded the maximum values found for
nevi
. The spatial patterns and expression levels of
JARID1B
did not change significantly with melanoma progression and were similar for primary, metastatic, and recurrent melanomas. Contrary to earlier reports, this study shows enhanced expression of
JARID1B
by melanoma cells and indicates that such an enhancement may be an early event in the disease progression, is not correlated with melanoma invasiveness, and therefore may not be a suitable candidate as a prognostic marker.
...
PMID:JARID1B expression in human melanoma and benign melanocytic skin lesions. 2326 39